With A New CEO, Will AstraZeneca Change Its Approach In Emerging Markets?
This article was originally published in PharmAsia News
Roche’s surging growth in China could hint at what’s coming to AstraZeneca in emerging markets as Pascal Soriot, Roche’s head of pharmaceuticals, takes over at AZ.
You may also be interested in...
AstraZeneca has appointed an experienced biotech and pharmaceuticals executive, Pascal Soriot, to its vacant CEO position, while Roche switches Daniel O'Day from its diagnostics to its pharmaceuticals division.
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City